Epiconcept, Paris, France; Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux F-33000, France.
Université Libre de Bruxelles, School of Public Health, Brussels, Belgium.
J Infect. 2017 Nov;75(5):381-394. doi: 10.1016/j.jinf.2017.09.010. Epub 2017 Sep 18.
Summary evidence of influenza vaccine effectiveness (IVE) against hospitalized influenza is lacking. We conducted a meta-analysis of studies reporting IVE against laboratory-confirmed hospitalized influenza among adults.
We searched Pubmed (January 2009 to November 2016) for studies that used test-negative design (TND) to enrol patients hospitalized with influenza-associated conditions. Two independent authors selected relevant articles. We calculated pooled IVE against any and (sub)type specific influenza among all adults, and stratified by age group (18-64 and 65 years and above) using random-effects models.
We identified 3411 publications and 30 met our inclusion criteria. Between 2010-11 and 2014-15, the pooled seasonal IVE was 41% (95%CI:34;48) for any influenza (51% (95%CI:44;58) among people aged 18-64y and 37% (95%CI:30;44) among ≥65 years). IVE was 48% (95%CI:37;59),37% (95%CI:24;50) and 38% (95%CI:23;53) against influenza A(H1N1)pdm09, A(H3N2) and B, respectively. Among persons aged ≥65 year, IVE against A(H3N2) was 43% (95%CI:33;53) in seasons when circulating and vaccine strains were antigenically similar and 14% (95%CI:-3;30) when A(H3N2) variant viruses predominated.
Influenza vaccines provided moderate protection against influenza-associated hospitalizations among adults. They seemed to provide low protection among elderly in seasons where vaccine and circulating A(H3N2) strains were antigenically variant.
目前缺乏流感疫苗有效性(IVE)对住院流感的综合证据。我们对报告了成年人中经实验室确诊的住院流感的 IVE 的研究进行了荟萃分析。
我们在 Pubmed(2009 年 1 月至 2016 年 11 月)中搜索了使用病例对照设计(TND)招募患有流感相关疾病的住院患者的研究。两位独立的作者选择了相关的文章。我们使用随机效应模型计算了所有成年人中针对任何和(亚)型流感的 IVE,按年龄组(18-64 岁和 65 岁及以上)进行分层。
我们确定了 3411 篇出版物,其中 30 篇符合我们的纳入标准。在 2010-11 年至 2014-15 年期间,任何流感的季节性 IVE 为 41%(95%CI:34%;48%)(18-64 岁人群中为 51%(95%CI:44%;58%),≥65 岁人群中为 37%(95%CI:30%;44%))。分别针对甲型流感(H1N1)pdm09、甲型流感(H3N2)和乙型流感的 IVE 为 48%(95%CI:37%;59%)、37%(95%CI:24%;50%)和 38%(95%CI:23%;53%)。在≥65 岁的人群中,当循环和疫苗株具有抗原相似性时,针对甲型流感(H3N2)的 IVE 为 43%(95%CI:33%;53%),而当甲型流感(H3N2)变异病毒占主导地位时,IVE 为 14%(95%CI:-3%;30%)。
流感疫苗对成年人的流感相关住院治疗提供了适度的保护。在疫苗株和循环株具有抗原变异的季节中,它们似乎对老年人提供了较低的保护。